The Cost of Not Retesting: Human Immunodeficiency Virus Misdiagnosis in the Antiretroviral Therapy "Test-and-Offer" Era.
Where this comes from
- Record sourced from PubMed, PMID 28444206.
- Also identified by DOI 10.1093/cid/cix341 and PMC identifier 5850410.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
We compared estimated costs of retesting human immunodeficiency virus (HIV)-positive persons before antiretroviral therapy (ART) initiation to the costs of ART provision to misdiagnosed HIV-negative persons. Savings from averted unnecessary ART costs were greater than retesting costs within 1 year using assumptions representative of HIV testing performance in programmatic settings. Countries should implement re-testing before ART initiation.
Medical subject headings
- Diagnostic Errors
- HIV Infections
- Models, Statistical